Lupin receives approval from FDA for Cyanocobalamin Nasal Spray
Cyanocobalamin Nasal Spray (RLD Nascobal) had estimated annual sales of USD 69 million in the U.S. (IQVIA MAT Mar 2023)
Cyanocobalamin Nasal Spray (RLD Nascobal) had estimated annual sales of USD 69 million in the U.S. (IQVIA MAT Mar 2023)
The zero-observation outcome reflects the company's robust quality management systems and commitment to excellence in its operations.
Dr. Reddy's aims to roll out its trade generics across cities and towns in India
The company expects to capture a 10 per cent share in Spain’s $6.34 million meropenem market and consolidate its position in other European countries
This product will be manufactured at Lupin's Pithampur facility in India
This trial is a multi-national, phase 2/3, open-label, randomized, controlled clinical study of utidelone injectable
Thiamine Hydrochloride Injection USP had estimated annual sales of USD 35 million in the U.S.
The inspection closed with the facility receiving an inspection classification of NAI
New facility will strengthen the security of supply for global pharmaceutical and biotech customers and will support the continued development and production of lifesaving clinical and commercial-scale therapeutics for patients worldwide.
Subscribe To Our Newsletter & Stay Updated